P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) [5][6] that belongs to the G i class of a group of G protein-coupled (GPCR) purinergic receptors. [7] . This P2Y receptor family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides.

The objectives of this review are to discuss the pharmacological limitations of the P2Y12 inhibitor clopidogrel, and describe the novel alternative P2Y12 inhibitors prasugrel and ticagrelor and the clinical implications of the introduction of these new medicines.

To determine the degree of platelet inhibition from the use of P2Y12 inhibition drug therapies known as thienopyridines. These include Clopidogrel (Plavix), Prasugrel, Ticlopidine (Ticlid), and Ticagrelor.

2024年7月14日 · Antiplatelet medicines work to make your platelets less sticky and thereby help prevent blood clots from forming in your arteries. Aspirin is an antiplatelet medicine that may be used. P2Y12 receptor blockers are another group of antiplatelet medicines.

The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses.

Platelet activation during disease states leads to vascular occlusion and ischemic damage. The P2Y 12 receptor, activated by ADP, plays a central role in platelet activation and is the target of P2Y 12 receptor antagonists that have proven therapeutic value.

Dual antiplatelet therapy (DAPT) has remained the cornerstone for management of acute coronary syndrome (ACS) over the years. Clopidogrel has been the quintessential P2Y12 receptor (platelet receptor for Adenosine 5′ diphosphate) inhibitor for the past two decades.